Chemenu’s Post

We are pleased to receive clearance from the FDA of our investigational new drug application for our novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). FR⍺ is a clinically validated target that is expressed in approximately 75% of ovarian carcinomas and 70% of non-small cell lung cancer. This is an exciting milestone for our team, showcasing the strength of our approach in developing best-in-class ADCs. For more information, see our press release: https://lnkd.in/eyXTC9VJ #OvarianCancer #LungCancer #NonSmallCellLungCancer #ADCs #AntibodyDrugConjugates #CancerResearch #Oncology #ClinicalTrials #DrugDevelopment

This post is intended for a US audience:   Today we announced the US FDA granted Priority Review for our HER2-directed antibody drug conjugate (ADC) – which we develop in collaboration with Daiichi Sankyo – for the potential treatment of certain patients with metastatic HER2-positive solid tumors.   HER2-directed therapies have been used for decades in breast cancer, where they have transformed outcomes for patients. Only recently has HER2 emerged as a treatment target for other types of solid tumors, creating an opportunity for us to address an important unmet need in patients. If approved, our ADC would potentially be the first HER2-directed treatment to receive a tumor-agnostic indication, aiding in our mission to redefine cancer care. Learn more about the news: https://lnkd.in/e_8Rajn3 #USOnly #AstraZenecaUS

This Cancer Research Month, we’d like to recognize the incredible efforts of the Remedy Plan Therapeutics Research Team, on the development of RPT1G, our clinical candidate being advanced for the treatment of hematologic cancers. RPT1G is Remedy Plan’s lead asset and the first partial inhibitor of NAMPT, meaning NAMPT is inhibited enough to stop the growth of cancer cells, but never turned down to zero, thereby allowing normal cells to function. The preclinical data generated with RPT1G is compelling and highly differentiated from that seen with other NAMPT inhibitors: RPT1G doesn't cause on-target toxicities seen by other NAMPT inhibitors and shows single-agent and combination efficacy in preclinical hematological disease models. Based on these promising data, we plan to submit our IND later this year and begin clinical testing. #NCRM24 #NAMPT #innovation

#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/eC_H9R8N #OvarianCancer #CancerTesting #Oncology

Partnership to Develop Next-Gen Radioligand Medicine for Rare Cancers!! 🤝 🎯 !! Collaboration between Sanofi, Radiomedix, Inc. and Orano Med focuses specifically on the late-stage project, AlphaMedix (212Pb-DOTAMTATE), which currently is being evaluated for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. AlphaMedixT is a targeted alpha therapy (TAT) which consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. #AlphaMedix has recently been granted Breakthrough Therapy Designation in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) from the US FDA for patients who are naïve to peptide-receptor radionuclide therapy. #sanofi #radiomedix #oranomed #competitiveintelligence #pharma #cancer

At BVD, we are harnessing TEM8/ANTXR1 – a protein highly expressed on cancer-associated cells – as a target for antibody drug conjugates (ADCs) to guide anti-cancer payloads into the tumor microenvironment. This therapeutic approach has shown promise across a range of solid tumor cancers and could be used either as a monotherapy or in combination with other anti-cancer agents. Find out more about the mechanism of action and data generated to date in our four-part educational video series here: https://lnkd.in/ewp6MZ2U #OvarianCancer #BreastCancer #LungCancer #ColonCancer #PancreaticCancer #ADC #AntibodyDrugConjugate #TumorMicroenvironment #Cancer #CancerReserach #Oncology #OncologyResearch 

Bispecific antibodies (bsAbs) allow therapeutic applications that cannot be achieved using conventional antibodies. There are 14 bsAbs approved: 11 for cancer & 3 for non-oncology indications. This review summarizes this very active field, including bsAb signaling pathway modulators, tumor-targeted receptor agonists, ADC, bispecific T cell, natural killer cell and checkpoint inhibitors. https://lnkd.in/e4KWKpPF

Advance your Non-Small Cell Lung Cancer (NSCLC) therapeutics with our premier NSCLC In Vivo Screen! Enroll Today: https://hubs.li/Q02FB3BV0 🗓️ Enroll by August 30th to access a comprehensive bank of 60 NSCLC PDX models, including crucial EGFR and KRAS mutant models. Each model is meticulously curated to preserve essential clinical and molecular characteristics for superior in vivo evaluation. Many models are pretreated with the latest targeted therapies, such as checkpoint inhibitors and EGFR-targeted treatments, closely mirroring clinically relevant patient responses. 💡Don't miss this cost-saving opportunity to advance your Non-Small Cell Lung Cancer therapeutics! #NSCLC #CancerResearch #DrugDevelopment #Biobank #PDXModels #CancerTherapeutics #EGFR #KRAS #NonSmallCellLungCancer #oncology #drugscreening #cancertherapy

It is the time for the unique combination.. New players in the track of metastatic NSCLC have been approved as first-line treatment. The EGFR inhibitor lazertinib (Lazcluze) in combination with the EGFR/MET-targeting bispecific antibody amivantamab-vmjw (Rybrevant) for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/ggFCd5RF #OvarianCancer #CancerTesting #Oncology